These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 39286240)

  • 1. Association of serum zinc with mineral stress in chronic kidney disease.
    Sohail A; Obereigner J; Mitter G; Schmid T; Hofer AS; Schuster G; Hügl A; Dorninger AH; Mandl M; Pasch A; Lackner HK; Papousek I; Dieplinger B; Suessner S; Antlanger M; Cejka D; Alesutan I; Voelkl J
    Clin Kidney J; 2024 Sep; 17(9):sfae258. PubMed ID: 39286240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with advanced chronic kidney disease and vascular calcification have a large hydrodynamic radius of secondary calciprotein particles.
    Chen W; Anokhina V; Dieudonne G; Abramowitz MK; Kashyap R; Yan C; Wu TT; de Mesy Bentley KL; Miller BL; Bushinsky DA
    Nephrol Dial Transplant; 2019 Jun; 34(6):992-1000. PubMed ID: 29788425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of Serum Calciprotein Particle Size and Transformation Time With Arterial Calcification, Arterial Stiffness, and Mortality in Incident Hemodialysis Patients.
    Chen W; Fitzpatrick J; Monroy-Trujillo JM; Sozio SM; Jaar BG; Estrella MM; Serrano J; Anokhina V; Miller BL; Melamed ML; Bushinsky DA; Parekh RS
    Am J Kidney Dis; 2021 Mar; 77(3):346-354. PubMed ID: 32800846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated calciprotein crystallization time (T50) is correlated with impaired lung diffusion capacity in systemic sclerosis.
    Geroldinger-Simic M; Sohail A; Razazian M; Krennmayr B; Pernsteiner V; Putz T; Lackner HK; Pasch A; Sepp N; Alesutan I; Voelkl J
    Front Immunol; 2024; 15():1425885. PubMed ID: 39399492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calciprotein particle inhibition explains magnesium-mediated protection against vascular calcification.
    Ter Braake AD; Eelderink C; Zeper LW; Pasch A; Bakker SJL; de Borst MH; Hoenderop JGJ; de Baaij JHF
    Nephrol Dial Transplant; 2020 May; 35(5):765-773. PubMed ID: 31605492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver and spleen predominantly mediate calciprotein particle clearance in a rat model of chronic kidney disease.
    Zeper LW; Bos C; Leermakers PA; Franssen GM; Raavé R; Hoenderop JGJ; de Baaij JHF
    Am J Physiol Renal Physiol; 2024 Apr; 326(4):F622-F634. PubMed ID: 38420675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review.
    Pluquet M; Kamel S; Choukroun G; Liabeuf S; Laville SM
    Toxins (Basel); 2022 Sep; 14(9):. PubMed ID: 36136575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum calcification propensity is associated with renal tissue oxygenation and resistive index in patients with arterial hypertension or chronic kidney disease.
    Pruijm M; Lu Y; Megdiche F; Piskunowicz M; Milani B; Stuber M; Bachtler M; Vogt B; Burnier M; Pasch A
    J Hypertens; 2017 Oct; 35(10):2044-2052. PubMed ID: 28562422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Calcification Propensity and Clinical Events in CKD.
    Bundy JD; Cai X; Mehta RC; Scialla JJ; de Boer IH; Hsu CY; Go AS; Dobre MA; Chen J; Rao PS; Leonard MB; Lash JP; Block GA; Townsend RR; Feldman HI; Smith ER; Pasch A; Isakova T;
    Clin J Am Soc Nephrol; 2019 Nov; 14(11):1562-1571. PubMed ID: 31658949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcification Propensity of Serum is Independent of Excretory Renal Function.
    Bielesz B; Reiter T; Marculescu R; Gleiss A; Bojic M; Kieweg H; Cejka D
    Sci Rep; 2017 Dec; 7(1):17941. PubMed ID: 29263429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial.
    Bressendorff I; Hansen D; Schou M; Pasch A; Brandi L
    Clin J Am Soc Nephrol; 2018 Sep; 13(9):1373-1380. PubMed ID: 30131425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Calcification Propensity and the Risk of Cardiovascular and All-Cause Mortality in the General Population: The PREVEND Study.
    Eelderink C; Te Velde-Keyzer CA; Frenay AS; Vermeulen EA; Bachtler M; Aghagolzadeh P; van Dijk PR; Gansevoort RT; Vervloet MG; Hillebrands JL; Bakker SJL; van Goor H; Pasch A; de Borst MH;
    Arterioscler Thromb Vasc Biol; 2020 Aug; 40(8):1942-1951. PubMed ID: 32493170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study.
    Bundy JD; Cai X; Scialla JJ; Dobre MA; Chen J; Hsu CY; Leonard MB; Go AS; Rao PS; Lash JP; Townsend RR; Feldman HI; de Boer IH; Block GA; Wolf M; Smith ER; Pasch A; Isakova T;
    Am J Kidney Dis; 2019 Jun; 73(6):806-814. PubMed ID: 30935773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Serum Zinc and Calcification Propensity (T
    Nakatani S; Mori K; Sonoda M; Nishide K; Uedono H; Tsuda A; Emoto M; Shoji T
    Biomedicines; 2020 Sep; 8(9):. PubMed ID: 32916995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Sodium Bicarbonate Supplementation Does Not Affect Serum Calcification Propensity in Patients with Chronic Kidney Disease and Chronic Metabolic Acidosis.
    Aigner C; Cejka D; Sliber C; Fraunschiel M; Sunder-Plassmann G; Gaggl M
    Kidney Blood Press Res; 2019; 44(2):188-199. PubMed ID: 31067546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity.
    Dekker M; Pasch A; van der Sande F; Konings C; Bachtler M; Dionisi M; Meier M; Kooman J; Canaud B
    PLoS One; 2016; 11(4):e0151508. PubMed ID: 27064679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum calcification propensity predicts all-cause mortality in predialysis CKD.
    Smith ER; Ford ML; Tomlinson LA; Bodenham E; McMahon LP; Farese S; Rajkumar C; Holt SG; Pasch A
    J Am Soc Nephrol; 2014 Feb; 25(2):339-48. PubMed ID: 24179171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.
    Vermeulen EA; Eelderink C; Hoekstra T; van Ballegooijen AJ; Raijmakers P; Beulens JW; de Borst MH; Vervloet MG
    Trials; 2022 Sep; 23(1):769. PubMed ID: 36096824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcification Propensity and Survival among Renal Transplant Recipients.
    Keyzer CA; de Borst MH; van den Berg E; Jahnen-Dechent W; Arampatzis S; Farese S; Bergmann IP; Floege J; Navis G; Bakker SJ; van Goor H; Eisenberger U; Pasch A
    J Am Soc Nephrol; 2016 Jan; 27(1):239-48. PubMed ID: 25925688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.
    Pasch A; Block GA; Bachtler M; Smith ER; Jahnen-Dechent W; Arampatzis S; Chertow GM; Parfrey P; Ma X; Floege J
    Clin J Am Soc Nephrol; 2017 Feb; 12(2):315-322. PubMed ID: 27940458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.